Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Pfizer Inc       

End-of-day quote. End-of-day quote  - 08/17
35.5 USD   +0.51%
10/02 JPMORGAN CHASE : Dow Movers: JPM, PFE
10/02 PFIZER : Announces Final Results of Exchange Offers
10/02 Novartis biosimilar copycat takes aim at Amgen's drug Enbrel
News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Pfizer CEO 2011 Compensation Valued At $25 Million, Up 44% Vs 2010

03/15/2012 | 04:07pm US/Eastern
  By Peter Loftus 

Pfizer Inc. (>> Pfizer Inc.) Chief Executive Ian Read received compensation valued at $25 million for 2011, up 44% from 2010, largely reflecting his promotion to the drug maker's top executive post in December 2010.

Read's compensation also was based partly on Pfizer exceeding targets set by the board's compensation committee for 2011 revenue, adjusted earnings and cash flow from operations, according to a proxy statement filed Thursday with the U.S. Securities and Exchange Commission.

The compensation committee cited Read's role in pursuing divestitures of noncore businesses and in returning cash to shareholders through dividends and share repurchases. Pfizer shares rose 23.6% for 2011.

Read, 58 years old, took over as Pfizer CEO in December 2010 when Jeffrey Kindler unexpectedly left the company. Read added the title of chairman of the board in December 2011.

For 2011, several elements of Read's compensation increased considerably. Stock awards rose to $5.7 million from $2.7 million, while the value of option awards surged to $6.9 million from less than $1 million, according to the proxy.

Read's salary was $1.7 million and his non-equity incentive plan compensation was $3.5 million. Other elements of his compensation: $6.9 million change in pension value and non-qualified deferred compensation earnings, and $319,000 in all other compensation.

For 2012, Read's salary will increase to $1.75 million, Pfizer said in the proxy.

Read, who joined Pfizer in 1978, has accumulated pension benefits with a total present value of about $27.4 million. In addition, the aggregate balance of Read's non-qualified deferred compensation is $8.2 million.

Pfizer Chief Financial Officer Frank D'Amelio received total compensation valued at $7.7 million for 2011, versus $6.5 million in 2010. Mikael Dolsten, president of worldwide research and development, received 2011 compensation valued at $7 million, up from $5.9 million for 2010.

Pfizer also disclosed in its proxy that its board compensation committee has made certain changes in executive pay in response to a disappointing shareholder advisory vote on executive compensation at last year's annual meeting.

The company has modified the terms of performance share awards so that they'll align more closely with performance, and has provided more a detailed explanation of its performance metrics, according to the proxy.

The compensation committee attributed the disappointing advisory vote at last year's annual shareholder meeting to dissatisfaction with the separation agreement with Kindler in late 2010. That agreement included a cash severance payment of $4.5 million and other compensation.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Pfizer Inc.
React to this article
Latest news on PFIZER INC
10/02 JPMORGAN CHASE : Dow Movers: JPM, PFE
10/02 PFIZER : Announces Final Results of Exchange Offers
10/02 Novartis biosimilar copycat takes aim at Amgen's drug Enbrel
10/01 PROVECTUS BIOPHARMACEUTICALS : Announces Initiation of Phase 1b/2 Clinical Trial..
10/01 PFIZER : Sayana® Press Becomes First Injectable Contraceptive In The United King..
10/01 PFIZER : Invites Public To View And Listen To Webcast Of Pfizer Presentation At ..
10/01 PFIZER : XRpro Sciences Completes Name Change to Icagen, Inc. Following Acquisit..
10/01 PFIZER : Announces Positive Top-Line Results from Two Phase 3 Trials of Oral Tof..
10/01 PFIZER : Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline
10/01 PFIZER : Assigned Patent
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Income Statement Evolution
More Financials